カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の抗血管新生点眼剤市場2023年：企業・地域・タイプ・用途別分析

■ 英語タイトル：Global Anti-angiogenic Ophthalmic Agent Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23SM7772）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23SM7772
■ 発行日：2023年9月
■ 調査対象地域：グローバル
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：126
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の抗血管新生点眼剤市場2023年：企業・地域・タイプ・用途別分析]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

GlobalInfoResearchの最新の調査によると、世界の抗血管新生点眼剤の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の抗血管新生点眼剤市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 抗血管新生点眼剤の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

抗血管新生点眼剤市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・近視性脈絡膜血管新生、黄斑浮腫、糖尿病網膜症、黄斑変性症

用途別セグメント
・小売薬局、オンライン薬局、病院薬局

主要な市場プレーヤー
・Gilead Sciences, Inc.、Eyetech Inc.、Becton, Dickinson and Company、Regeneron Pharmaceuticals, Inc.、Genentech, Inc.、Novartis AG、Allergan plc、Bayer AG、Santen Pharmaceutical Co., Ltd.、Shanghai Pharmaceuticals、Johnson & Johnson、Pfizer、Sun Pharma、Otsuka Pharmaceutical Co. Ltd、Daiichi Sankyo、ERC Labs、Medicom Health care、Implant ophthalmic products GmbH、The Geuder Group, MORCHER GmbH、Novamedika

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、抗血管新生点眼剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な抗血管新生点眼剤メーカーの企業概要、2019年～2022年までの抗血管新生点眼剤の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な抗血管新生点眼剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別抗血管新生点眼剤の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの抗血管新生点眼剤のタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での抗血管新生点眼剤市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および抗血管新生点眼剤の産業チェーンを掲載しています。
・第14、15章では、抗血管新生点眼剤の販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– 抗血管新生点眼剤の概要
– タイプ別分析（2018年vs2022年vs2029年）：近視性脈絡膜血管新生、黄斑浮腫、糖尿病網膜症、黄斑変性症
– 用途別分析（2018年vs2022年vs2029年）：小売薬局、オンライン薬局、病院薬局
– 世界の抗血管新生点眼剤市場規模・予測
– 世界の抗血管新生点眼剤生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Gilead Sciences, Inc.、Eyetech Inc.、Becton, Dickinson and Company、Regeneron Pharmaceuticals, Inc.、Genentech, Inc.、Novartis AG、Allergan plc、Bayer AG、Santen Pharmaceutical Co., Ltd.、Shanghai Pharmaceuticals、Johnson & Johnson、Pfizer、Sun Pharma、Otsuka Pharmaceutical Co. Ltd、Daiichi Sankyo、ERC Labs、Medicom Health care、Implant ophthalmic products GmbH、The Geuder Group, MORCHER GmbH、Novamedika
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：近視性脈絡膜血管新生、黄斑浮腫、糖尿病網膜症、黄斑変性症
・用途別分析2018年-2029年：小売薬局、オンライン薬局、病院薬局
・抗血管新生点眼剤の北米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・抗血管新生点眼剤のヨーロッパ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・抗血管新生点眼剤のアジア市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・抗血管新生点眼剤の南米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・抗血管新生点眼剤の中東・アフリカ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Anti-angiogenic Ophthalmic Agent
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Anti-angiogenic Ophthalmic Agent Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Myopic Choroidal Neovascularization
1.3.3 Macular Edema
1.3.4 Diabetic Retinopathy
1.3.5 Macular Degeneration
1.4 Market Analysis by Application
1.4.1 Overview: Global Anti-angiogenic Ophthalmic Agent Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Retail Pharmacies
1.4.3 Online Pharmacies
1.4.4 Hospital Pharmacies
1.5 Global Anti-angiogenic Ophthalmic Agent Market Size & Forecast
1.5.1 Global Anti-angiogenic Ophthalmic Agent Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Anti-angiogenic Ophthalmic Agent Sales Quantity (2018-2029)
1.5.3 Global Anti-angiogenic Ophthalmic Agent Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Gilead Sciences, Inc.
2.1.1 Gilead Sciences, Inc. Details
2.1.2 Gilead Sciences, Inc. Major Business
2.1.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
2.1.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Gilead Sciences, Inc. Recent Developments/Updates
2.2 Eyetech Inc.
2.2.1 Eyetech Inc. Details
2.2.2 Eyetech Inc. Major Business
2.2.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product and Services
2.2.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Eyetech Inc. Recent Developments/Updates
2.3 Becton, Dickinson and Company
2.3.1 Becton, Dickinson and Company Details
2.3.2 Becton, Dickinson and Company Major Business
2.3.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product and Services
2.3.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Becton, Dickinson and Company Recent Developments/Updates
2.4 Regeneron Pharmaceuticals, Inc.
2.4.1 Regeneron Pharmaceuticals, Inc. Details
2.4.2 Regeneron Pharmaceuticals, Inc. Major Business
2.4.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
2.4.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
2.5 Genentech, Inc.
2.5.1 Genentech, Inc. Details
2.5.2 Genentech, Inc. Major Business
2.5.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
2.5.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Genentech, Inc. Recent Developments/Updates
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business
2.6.3 Novartis AG Anti-angiogenic Ophthalmic Agent Product and Services
2.6.4 Novartis AG Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Novartis AG Recent Developments/Updates
2.7 Allergan plc
2.7.1 Allergan plc Details
2.7.2 Allergan plc Major Business
2.7.3 Allergan plc Anti-angiogenic Ophthalmic Agent Product and Services
2.7.4 Allergan plc Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Allergan plc Recent Developments/Updates
2.8 Bayer AG
2.8.1 Bayer AG Details
2.8.2 Bayer AG Major Business
2.8.3 Bayer AG Anti-angiogenic Ophthalmic Agent Product and Services
2.8.4 Bayer AG Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Bayer AG Recent Developments/Updates
2.9 Santen Pharmaceutical Co., Ltd.
2.9.1 Santen Pharmaceutical Co., Ltd. Details
2.9.2 Santen Pharmaceutical Co., Ltd. Major Business
2.9.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product and Services
2.9.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
2.10 Shanghai Pharmaceuticals
2.10.1 Shanghai Pharmaceuticals Details
2.10.2 Shanghai Pharmaceuticals Major Business
2.10.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product and Services
2.10.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Shanghai Pharmaceuticals Recent Developments/Updates
2.11 Johnson & Johnson
2.11.1 Johnson & Johnson Details
2.11.2 Johnson & Johnson Major Business
2.11.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product and Services
2.11.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Johnson & Johnson Recent Developments/Updates
2.12 Pfizer
2.12.1 Pfizer Details
2.12.2 Pfizer Major Business
2.12.3 Pfizer Anti-angiogenic Ophthalmic Agent Product and Services
2.12.4 Pfizer Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Pfizer Recent Developments/Updates
2.13 Sun Pharma
2.13.1 Sun Pharma Details
2.13.2 Sun Pharma Major Business
2.13.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Product and Services
2.13.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Sun Pharma Recent Developments/Updates
2.14 Otsuka Pharmaceutical Co. Ltd
2.14.1 Otsuka Pharmaceutical Co. Ltd Details
2.14.2 Otsuka Pharmaceutical Co. Ltd Major Business
2.14.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product and Services
2.14.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Otsuka Pharmaceutical Co. Ltd Recent Developments/Updates
2.15 Daiichi Sankyo
2.15.1 Daiichi Sankyo Details
2.15.2 Daiichi Sankyo Major Business
2.15.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product and Services
2.15.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Daiichi Sankyo Recent Developments/Updates
2.16 ERC Labs
2.16.1 ERC Labs Details
2.16.2 ERC Labs Major Business
2.16.3 ERC Labs Anti-angiogenic Ophthalmic Agent Product and Services
2.16.4 ERC Labs Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 ERC Labs Recent Developments/Updates
2.17 Medicom Health care
2.17.1 Medicom Health care Details
2.17.2 Medicom Health care Major Business
2.17.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Product and Services
2.17.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Medicom Health care Recent Developments/Updates
2.18 Implant ophthalmic products GmbH
2.18.1 Implant ophthalmic products GmbH Details
2.18.2 Implant ophthalmic products GmbH Major Business
2.18.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product and Services
2.18.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Implant ophthalmic products GmbH Recent Developments/Updates
2.19 The Geuder Group, MORCHER GmbH
2.19.1 The Geuder Group, MORCHER GmbH Details
2.19.2 The Geuder Group, MORCHER GmbH Major Business
2.19.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product and Services
2.19.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 The Geuder Group, MORCHER GmbH Recent Developments/Updates
2.20 Novamedika
2.20.1 Novamedika Details
2.20.2 Novamedika Major Business
2.20.3 Novamedika Anti-angiogenic Ophthalmic Agent Product and Services
2.20.4 Novamedika Anti-angiogenic Ophthalmic Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Novamedika Recent Developments/Updates
3 Competitive Environment: Anti-angiogenic Ophthalmic Agent by Manufacturer
3.1 Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Manufacturer (2018-2023)
3.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturer (2018-2023)
3.3 Global Anti-angiogenic Ophthalmic Agent Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Anti-angiogenic Ophthalmic Agent by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Anti-angiogenic Ophthalmic Agent Manufacturer Market Share in 2022
3.4.2 Top 6 Anti-angiogenic Ophthalmic Agent Manufacturer Market Share in 2022
3.5 Anti-angiogenic Ophthalmic Agent Market: Overall Company Footprint Analysis
3.5.1 Anti-angiogenic Ophthalmic Agent Market: Region Footprint
3.5.2 Anti-angiogenic Ophthalmic Agent Market: Company Product Type Footprint
3.5.3 Anti-angiogenic Ophthalmic Agent Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Anti-angiogenic Ophthalmic Agent Market Size by Region
4.1.1 Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Region (2018-2029)
4.1.2 Global Anti-angiogenic Ophthalmic Agent Consumption Value by Region (2018-2029)
4.1.3 Global Anti-angiogenic Ophthalmic Agent Average Price by Region (2018-2029)
4.2 North America Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029)
4.3 Europe Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029)
4.4 Asia-Pacific Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029)
4.5 South America Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029)
4.6 Middle East and Africa Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
5.2 Global Anti-angiogenic Ophthalmic Agent Consumption Value by Type (2018-2029)
5.3 Global Anti-angiogenic Ophthalmic Agent Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
6.2 Global Anti-angiogenic Ophthalmic Agent Consumption Value by Application (2018-2029)
6.3 Global Anti-angiogenic Ophthalmic Agent Average Price by Application (2018-2029)
7 North America
7.1 North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
7.2 North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
7.3 North America Anti-angiogenic Ophthalmic Agent Market Size by Country
7.3.1 North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2029)
7.3.2 North America Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
8.2 Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
8.3 Europe Anti-angiogenic Ophthalmic Agent Market Size by Country
8.3.1 Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2029)
8.3.2 Europe Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size by Region
9.3.1 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Anti-angiogenic Ophthalmic Agent Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
10.2 South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
10.3 South America Anti-angiogenic Ophthalmic Agent Market Size by Country
10.3.1 South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2029)
10.3.2 South America Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Anti-angiogenic Ophthalmic Agent Market Size by Country
11.3.1 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Anti-angiogenic Ophthalmic Agent Market Drivers
12.2 Anti-angiogenic Ophthalmic Agent Market Restraints
12.3 Anti-angiogenic Ophthalmic Agent Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Anti-angiogenic Ophthalmic Agent and Key Manufacturers
13.2 Manufacturing Costs Percentage of Anti-angiogenic Ophthalmic Agent
13.3 Anti-angiogenic Ophthalmic Agent Production Process
13.4 Anti-angiogenic Ophthalmic Agent Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Anti-angiogenic Ophthalmic Agent Typical Distributors
14.3 Anti-angiogenic Ophthalmic Agent Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Anti-angiogenic Ophthalmic Agent Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Anti-angiogenic Ophthalmic Agent Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 4. Gilead Sciences, Inc. Major Business
Table 5. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 6. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Gilead Sciences, Inc. Recent Developments/Updates
Table 8. Eyetech Inc. Basic Information, Manufacturing Base and Competitors
Table 9. Eyetech Inc. Major Business
Table 10. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 11. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Eyetech Inc. Recent Developments/Updates
Table 13. Becton, Dickinson and Company Basic Information, Manufacturing Base and Competitors
Table 14. Becton, Dickinson and Company Major Business
Table 15. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product and Services
Table 16. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Becton, Dickinson and Company Recent Developments/Updates
Table 18. Regeneron Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 19. Regeneron Pharmaceuticals, Inc. Major Business
Table 20. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 21. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
Table 23. Genentech, Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Genentech, Inc. Major Business
Table 25. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 26. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Genentech, Inc. Recent Developments/Updates
Table 28. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 29. Novartis AG Major Business
Table 30. Novartis AG Anti-angiogenic Ophthalmic Agent Product and Services
Table 31. Novartis AG Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Novartis AG Recent Developments/Updates
Table 33. Allergan plc Basic Information, Manufacturing Base and Competitors
Table 34. Allergan plc Major Business
Table 35. Allergan plc Anti-angiogenic Ophthalmic Agent Product and Services
Table 36. Allergan plc Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Allergan plc Recent Developments/Updates
Table 38. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 39. Bayer AG Major Business
Table 40. Bayer AG Anti-angiogenic Ophthalmic Agent Product and Services
Table 41. Bayer AG Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Bayer AG Recent Developments/Updates
Table 43. Santen Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 44. Santen Pharmaceutical Co., Ltd. Major Business
Table 45. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product and Services
Table 46. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 48. Shanghai Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 49. Shanghai Pharmaceuticals Major Business
Table 50. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product and Services
Table 51. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Shanghai Pharmaceuticals Recent Developments/Updates
Table 53. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 54. Johnson & Johnson Major Business
Table 55. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product and Services
Table 56. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Johnson & Johnson Recent Developments/Updates
Table 58. Pfizer Basic Information, Manufacturing Base and Competitors
Table 59. Pfizer Major Business
Table 60. Pfizer Anti-angiogenic Ophthalmic Agent Product and Services
Table 61. Pfizer Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Pfizer Recent Developments/Updates
Table 63. Sun Pharma Basic Information, Manufacturing Base and Competitors
Table 64. Sun Pharma Major Business
Table 65. Sun Pharma Anti-angiogenic Ophthalmic Agent Product and Services
Table 66. Sun Pharma Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Sun Pharma Recent Developments/Updates
Table 68. Otsuka Pharmaceutical Co. Ltd Basic Information, Manufacturing Base and Competitors
Table 69. Otsuka Pharmaceutical Co. Ltd Major Business
Table 70. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product and Services
Table 71. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Otsuka Pharmaceutical Co. Ltd Recent Developments/Updates
Table 73. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 74. Daiichi Sankyo Major Business
Table 75. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product and Services
Table 76. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Daiichi Sankyo Recent Developments/Updates
Table 78. ERC Labs Basic Information, Manufacturing Base and Competitors
Table 79. ERC Labs Major Business
Table 80. ERC Labs Anti-angiogenic Ophthalmic Agent Product and Services
Table 81. ERC Labs Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. ERC Labs Recent Developments/Updates
Table 83. Medicom Health care Basic Information, Manufacturing Base and Competitors
Table 84. Medicom Health care Major Business
Table 85. Medicom Health care Anti-angiogenic Ophthalmic Agent Product and Services
Table 86. Medicom Health care Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Medicom Health care Recent Developments/Updates
Table 88. Implant ophthalmic products GmbH Basic Information, Manufacturing Base and Competitors
Table 89. Implant ophthalmic products GmbH Major Business
Table 90. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product and Services
Table 91. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. Implant ophthalmic products GmbH Recent Developments/Updates
Table 93. The Geuder Group, MORCHER GmbH Basic Information, Manufacturing Base and Competitors
Table 94. The Geuder Group, MORCHER GmbH Major Business
Table 95. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product and Services
Table 96. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 97. The Geuder Group, MORCHER GmbH Recent Developments/Updates
Table 98. Novamedika Basic Information, Manufacturing Base and Competitors
Table 99. Novamedika Major Business
Table 100. Novamedika Anti-angiogenic Ophthalmic Agent Product and Services
Table 101. Novamedika Anti-angiogenic Ophthalmic Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 102. Novamedika Recent Developments/Updates
Table 103. Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 104. Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturer (2018-2023) & (USD Million)
Table 105. Global Anti-angiogenic Ophthalmic Agent Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 106. Market Position of Manufacturers in Anti-angiogenic Ophthalmic Agent, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 107. Head Office and Anti-angiogenic Ophthalmic Agent Production Site of Key Manufacturer
Table 108. Anti-angiogenic Ophthalmic Agent Market: Company Product Type Footprint
Table 109. Anti-angiogenic Ophthalmic Agent Market: Company Product Application Footprint
Table 110. Anti-angiogenic Ophthalmic Agent New Market Entrants and Barriers to Market Entry
Table 111. Anti-angiogenic Ophthalmic Agent Mergers, Acquisition, Agreements, and Collaborations
Table 112. Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Region (2018-2023) & (K Units)
Table 113. Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Region (2024-2029) & (K Units)
Table 114. Global Anti-angiogenic Ophthalmic Agent Consumption Value by Region (2018-2023) & (USD Million)
Table 115. Global Anti-angiogenic Ophthalmic Agent Consumption Value by Region (2024-2029) & (USD Million)
Table 116. Global Anti-angiogenic Ophthalmic Agent Average Price by Region (2018-2023) & (US$/Unit)
Table 117. Global Anti-angiogenic Ophthalmic Agent Average Price by Region (2024-2029) & (US$/Unit)
Table 118. Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 119. Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 120. Global Anti-angiogenic Ophthalmic Agent Consumption Value by Type (2018-2023) & (USD Million)
Table 121. Global Anti-angiogenic Ophthalmic Agent Consumption Value by Type (2024-2029) & (USD Million)
Table 122. Global Anti-angiogenic Ophthalmic Agent Average Price by Type (2018-2023) & (US$/Unit)
Table 123. Global Anti-angiogenic Ophthalmic Agent Average Price by Type (2024-2029) & (US$/Unit)
Table 124. Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Global Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Global Anti-angiogenic Ophthalmic Agent Consumption Value by Application (2018-2023) & (USD Million)
Table 127. Global Anti-angiogenic Ophthalmic Agent Consumption Value by Application (2024-2029) & (USD Million)
Table 128. Global Anti-angiogenic Ophthalmic Agent Average Price by Application (2018-2023) & (US$/Unit)
Table 129. Global Anti-angiogenic Ophthalmic Agent Average Price by Application (2024-2029) & (US$/Unit)
Table 130. North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 131. North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 132. North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 133. North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 134. North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2023) & (K Units)
Table 135. North America Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2024-2029) & (K Units)
Table 136. North America Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2023) & (USD Million)
Table 137. North America Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2024-2029) & (USD Million)
Table 138. Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 139. Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 140. Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 141. Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 142. Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2023) & (K Units)
Table 143. Europe Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2024-2029) & (K Units)
Table 144. Europe Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2023) & (USD Million)
Table 145. Europe Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2024-2029) & (USD Million)
Table 146. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 147. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 148. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 149. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 150. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Region (2018-2023) & (K Units)
Table 151. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity by Region (2024-2029) & (K Units)
Table 152. Asia-Pacific Anti-angiogenic Ophthalmic Agent Consumption Value by Region (2018-2023) & (USD Million)
Table 153. Asia-Pacific Anti-angiogenic Ophthalmic Agent Consumption Value by Region (2024-2029) & (USD Million)
Table 154. South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 155. South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 156. South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 157. South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 158. South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2018-2023) & (K Units)
Table 159. South America Anti-angiogenic Ophthalmic Agent Sales Quantity by Country (2024-2029) & (K Units)
Table 160. South America Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2018-2023) & (USD Million)
Table 161. South America Anti-angiogenic Ophthalmic Agent Consumption Value by Country (2024-2029) & (USD Million)
Table 162. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 163. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 164. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 165. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 166. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Region (2018-2023) & (K Units)
Table 167. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity by Region (2024-2029) & (K Units)
Table 168. Middle East & Africa Anti-angiogenic Ophthalmic Agent Consumption Value by Region (2018-2023) & (USD Million)
Table 169. Middle East & Africa Anti-angiogenic Ophthalmic Agent Consumption Value by Region (2024-2029) & (USD Million)
Table 170. Anti-angiogenic Ophthalmic Agent Raw Material
Table 171. Key Manufacturers of Anti-angiogenic Ophthalmic Agent Raw Materials
Table 172. Anti-angiogenic Ophthalmic Agent Typical Distributors
Table 173. Anti-angiogenic Ophthalmic Agent Typical Customers
List of Figures
Figure 1. Anti-angiogenic Ophthalmic Agent Picture
Figure 2. Global Anti-angiogenic Ophthalmic Agent Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Type in 2022
Figure 4. Myopic Choroidal Neovascularization Examples
Figure 5. Macular Edema Examples
Figure 6. Diabetic Retinopathy Examples
Figure 7. Macular Degeneration Examples
Figure 8. Global Anti-angiogenic Ophthalmic Agent Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Application in 2022
Figure 10. Retail Pharmacies Examples
Figure 11. Online Pharmacies Examples
Figure 12. Hospital Pharmacies Examples
Figure 13. Global Anti-angiogenic Ophthalmic Agent Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Anti-angiogenic Ophthalmic Agent Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Anti-angiogenic Ophthalmic Agent Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Anti-angiogenic Ophthalmic Agent Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Anti-angiogenic Ophthalmic Agent by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Anti-angiogenic Ophthalmic Agent Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Anti-angiogenic Ophthalmic Agent Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Anti-angiogenic Ophthalmic Agent Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Anti-angiogenic Ophthalmic Agent Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Anti-angiogenic Ophthalmic Agent Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Region (2018-2029)
Figure 55. China Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Anti-angiogenic Ophthalmic Agent Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Anti-angiogenic Ophthalmic Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Anti-angiogenic Ophthalmic Agent Market Drivers
Figure 76. Anti-angiogenic Ophthalmic Agent Market Restraints
Figure 77. Anti-angiogenic Ophthalmic Agent Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Anti-angiogenic Ophthalmic Agent in 2022
Figure 80. Manufacturing Process Analysis of Anti-angiogenic Ophthalmic Agent
Figure 81. Anti-angiogenic Ophthalmic Agent Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の工業用バリ止め防錆剤市場2023年：企業・地域・タイプ・用途別分析
  • 世界のデスクトップ型眼科用超音波診断装置市場2023年：企業・地域・タイプ・用途別分析
  • 世界のNSAID点眼薬市場2023年：企業・地域・タイプ・用途別分析
  • 世界の眼科超音波乳化吸引術治療装置市場2023年：企業・地域・タイプ・用途別分析
  • 世界の粘膜下注射剤市場2023年：企業・地域・タイプ・用途別分析
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23SM7772 )"世界の抗血管新生点眼剤市場2023年：企業・地域・タイプ・用途別分析" (英文：Global Anti-angiogenic Ophthalmic Agent Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。